EASL Recommendations
on Treatment of Hepatitis C 2014
Genotype 1
Recommendations
* Patients infected with HCV genotype 1 can be treated
with a combination of weekly pegylated IFN-α, daily
weight-based ribavirin (1000 or 1200 mg in patients <75
kg or ≥75 kg, respectively), and daily simeprevir (150
mg) (Recommendation A1)
* This combination is not recommended in patients
infected with subtype 1a who have a detectable Q80K
substitution in the NS3 protease sequence at baseline,
as assessed by population sequencing (direct sequence
analysis) (Recommendation A2)
* Simeprevir should be administered 12 weeks in
combination with pegylated IFN-α and ribavirin.
Pegylated IFN-α and ribavirin should then be
administered alone for an additional 12 weeks (total
treatment duration 24 weeks) in treatment-naïve and
prior relapser patients, including cirrhotics,
and for an additional 36 weeks (total treatment duration 48 weeks)
in prior partial and null responders, including cirrhotics
(Recommendation B1)
* HCV RNA levels should be monitored on treatment.
Treatment should be stopped if HCV RNA level is
≥25 IU/ml at treatment week 4, week 12 or week 24
В Европейских рекомендациях у первичных пациентов, включая пациентов с циррозом, общая длительность лечения 24 недели.
Учитывая наличие диабета в качестве фактора снижающего эффективность терапии, я бы лечил дольше при отсутствии противопоказаний.
|